# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its ...
BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $23 to $21.
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $21 to $20.
Craig-Hallum analyst Alex Nowark assumes NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $26.
Benchmark analyst Bruce Jackson reiterates NeoGenomics (NASDAQ:NEO) with a Buy and maintains $18 price target.
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $24 to $19.